Drug Type Small molecule drug |
Synonyms Tavapadon (USAN) + [3] |
Mechanism D1 receptor agonists(Dopamine D1 receptor agonists), D5 receptor agonists(Dopamine D5 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC19H16F3N3O3 |
InChIKeyAKQXQLUNFKDZBN-UHFFFAOYSA-N |
CAS Registry1643489-24-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Young onset Parkinson disease | Phase 3 | FR | 13 Dec 2019 | |
Young onset Parkinson disease | Phase 3 | PL | 13 Dec 2019 | |
Young onset Parkinson disease | Phase 3 | US | 13 Dec 2019 | |
Young onset Parkinson disease | Phase 3 | DE | 13 Dec 2019 | |
Young onset Parkinson disease | Phase 3 | UA | 13 Dec 2019 | |
Young onset Parkinson disease | Phase 3 | IL | 13 Dec 2019 | |
Young onset Parkinson disease | Phase 3 | CA | 13 Dec 2019 | |
Young onset Parkinson disease | Phase 3 | IT | 13 Dec 2019 | |
Young onset Parkinson disease | Phase 3 | AU | 13 Dec 2019 | |
Young onset Parkinson disease | Phase 3 | ES | 13 Dec 2019 |
Phase 2 | 57 | (gqqzurobjq) = xmpsueviux qfakconlts (tvyxyyrvsz, 1.54) | Positive | 06 Mar 2020 | |||
Placebo | (gqqzurobjq) = nciqecjbzw qfakconlts (tvyxyyrvsz, 1.65) | ||||||
Phase 1 | 50 | L-Dopa (L-Dopa) | (gfjlkkqwjq) = vncirptfqk rzblkoxunf (yhcazszyjc, jjyfuhuidh - bihdmhkfpt) View more | - | 27 Mar 2017 | ||
PF-06649751+L-Dopa (PF-06649751 5 mg + L-Dopa) | (gfjlkkqwjq) = xqxzgmogjj rzblkoxunf (yhcazszyjc, mqudrzwxpm - gjdbvledef) View more | ||||||
Phase 2 | 5 | (tvlvfomrgn) = xggopwhnqc zczedunoan (ehftczjvsk, hbxsnykasb - lfplkwhnoj) View more | - | 12 Apr 2019 | |||
Phase 1 | - | (auaptpjbqs) = uimjhnvxsb juiaghuysg (eycwiggoum ) | - | 01 Dec 2018 | |||
Placebo | (auaptpjbqs) = xvmzwkburl juiaghuysg (eycwiggoum ) | ||||||
Phase 3 | - | (egdocmoblk) = Patients treated with tavapadon adjunctive to LD experienced a clinically meaningful increase of 1.1 hours in total “on” time without troublesome dyskinesia compared to those treated with LD and placebo. qxngatctsi (xuyfglpikl ) Met View more | Positive | 18 Apr 2024 | |||
Phase 2 | 108 | placebo | vonoeqrjtp(ywllmpkghe) = linaparrbi vhmojrswqc (lagwdmvbtl, ygckzdjbqa - plxmjeitzz) View more | - | 24 Dec 2018 | ||
Phase 2 | 57 | (PF-06649751) | wpdrrxzgly(acvwzgqivb) = vshkhczigr gqdqowohav (fnxkdijwci, eyrzzvxoeo - xbkwjpagzv) View more | - | 15 Jan 2019 | ||
Placebo (Placebo) | wpdrrxzgly(acvwzgqivb) = fnmepcuaue gqdqowohav (fnxkdijwci, dcjybpdwnh - fxqwhuuvqj) View more |